This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

ertugliflozin/sitagliptin (Steglujan®)

Reference No. 1104

Publication date:

Appraisal information

ertugliflozin/sitagliptin (Steglujan®) 5 mg/ 100 mg film-coated tablet
ertugliflozin/sitagliptin (Steglujan®) 15 mg/100 mg film-coated tablet

Company: Merck Sharp & Dohme Ltd
BNF category: Endocrine system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 23/07/2018

Current Progress

Ratification by
Welsh Government

AWMSG advice

This product is currently not marketed in the UK. In the absence of a submission from the holder of the marketing authorisation, ertugliflozin/sitagliptin (Steglujan®) cannot be endorsed for use within NHS Wales for use as an adjunct to diet and exercise to improve glycaemic control in adults aged 18 years and older with type 2 diabetes mellitus: when metformin and/or a sulphonylurea and one of the monocomponents of Steglujan® do not provide adequate glycaemic control; in patients already being treated with the combination of ertugliflozin and sitagliptin as separate tablets.
Statement of Advice (SOA)